Glycophos Injectable Product
Small molecule
Glycophos Injectable Product is one of 10 small molecule programs targeting Hypophosphatemia. It is currently in development.
1
Indications
2
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
12 competitors in Hypophosphatemia
#DrugCompanyPhaseTrials
1Calciferol
Alnylam PharmaceuticalsApproved
Iron Carboxymaltose
HHospital de Clinicas de Porto Alegre
Approved
Iron Isomaltoside
TThomas Jefferson University
Approved
Antibiotics
MMelinta Therapeutics, Inc.
Approved
Injectafer
AAmerican Regent, Inc.
Phase 3
Iron Sulphate
PPierre Fabre Pharma GmbH
Phase 3
Inotropes
AAmsterdam UMC, location VUmc
Approved
Dexferrum
NNew River Pharmaceuticals
Phase 2
Nexavar
BayerPhase 1
Glycophos Injectable Product
AAin Shams University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypophosphatemia2 trials
The Efficacy and Safety of Diluted Oral Phosphate Enema Versus Intravenous Sodium Glycerophosphate in The Treatment of Hypophosphatemia in ICU Patients
Completed·—·Phase 2/3·NCT06651892·42 enrolled
Levels of 'Hypophosphatemia Affect Outcome of Septic Patients in ICU
Unknown status·—·Phase 4·NCT04519762·100 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- AAin Shams University